Author pages are created from data sourced from our academic publisher partnerships and public sources.
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
- C. Polman, F. Barkhof, M. Sandberg‐Wollheim, A. Linde, O. Nordle, T. Nederman
- 22 March 2005
Background: Laquinimod is a novel immunomodulatory substance developed as an orally available disease modifying treatment in multiple sclerosis (MS). The purpose of this study was to evaluate safety,… Expand
Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
- G. Forsberg, Niels-Jörgen Skartved, +4 authors T. Nederman
- Medicine, Biology
- Journal of immunotherapy
- 1 June 2010
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has identified several issues that need to be addressed to optimize such… Expand
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
- C. Sternberg, A. Armstrong, +23 authors M. Carducci
- Journal of clinical oncology : official journal…
- 1 August 2016
PURPOSE Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with… Expand